Recently, WeiΔbach et al. [13] reported that the occurrence of DIS3 mutations in minor subclones was significantly associated with a weaker chemotherapy response as compared to the DIS3 mutations in major subclones, while globally there was only a slight trend towards shorter median overall survival for DIS3-mutated MM patients as compared to DIS3 wild type ones. This evidence concerns the gene DIS3 and Miyoshi myopathy.